Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of orvepitant in chronic treatment-refractory cough
2014-003947-36Phase 2Completed
- Sponsor
- NeRRe Therapeutics
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of orvepitant in chronic idiopathic cough (CIC) and chronic cough, sponsored by NeRRe Therapeutics. Primary endpoint: Change in objective daytime cough frequency at Week 4 vs Baseline. Started Oct 2014; status: completed.
02
Drugs
orvepitant
03
Conditions
chronic idiopathic cough (CIC)chronic cough
Beyond the preview
Go deeper on 2014-003947-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003947-36.